CUV
CLINUVEL PHARMACEUTICALS LIMITED
$7.59
▲ +2.29%
Market cap
$383M
Turnover
$738,957
Last price
$7.59
Day change
+2.29%
Announcements
14
Range, past year
Open 11.12 · Low 6.620 · Now 7.590 · High 14.00
Open CUV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CUV momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
38/100
Wyckoff phase
Downtrend24d
Trend stage
Neutral
1 Day
+2.3%
1 Week
+0.3%
1 Month
+0.4%
1 Year
-31.5%
RSI
51
Avg daily range
4.7%
CLINUVEL PHARMACEUTICALS LIMITED scores 38 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Downtrend, where it has been for 24 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
What stands out
- MACD histogram positive & rising
Points to watch
- 60d drawdown -33.9%
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCUV announcements
Recent price-sensitive releases.
- 2026-11-06 Managing Director Address Company Presentation | Chair's Address - Other
- 2026-10-30 CLINUVEL files NEURACTHEL Instant dossier Progress Report
- 2026-08-27 CLINUVEL considers Nasdaq listing, ASX delisting Company Administration - Other
- 2026-08-27 Investor Presentation Company Presentation | Preliminary Final Report
- 2026-08-27 A decade of profitability provides U.S. expansion foundation Preliminary Final Report
- 2026-08-27 Appendix 4E and Annual Report to Shareholders 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report | Dividend Record Date | Dividend Rate
- 2026-07-30 Commercial update on vitiligo Progress Report
More Health Care stocks
Most traded in the same sector.